Structures by: Zhou L. N.
Total: 21
Ciclesonide cyclohexane solvate
C35H50O7
RSC Adv. (2016)
a=14.955(3)Å b=32.318(7)Å c=6.8184(14)Å
α=90.00° β=90.00° γ=90.00°
Ciclesonide methanol solvate
C33H48O8
RSC Adv. (2016)
a=11.0007(11)Å b=11.0007(11)Å c=25.559(4)Å
α=90.00° β=90.00° γ=90.00°
C8H6O4
C8H6O4
Acta Crystallographica Section E (2006) 62, 5 o1893-o1894
a=7.0685(14)Å b=7.1553(14)Å c=8.1436(16)Å
α=90.39(3)° β=107.51(3)° γ=114.06(3)°
Catena-Poly[[silver(I)-μ-1-phenylsulfanyl-2-(2-pyridylsulfanyl)ethane- κ^2^S^1^:N^2^] tetrafluoroborate]
C13H13AgNS2,B1F4
Acta Crystallographica Section E (2005) 61, 10 m2095-m2096
a=11.252(3)Å b=13.999(4)Å c=11.315(3)Å
α=90.00° β=116.227(4)° γ=90.00°
Carbonyliodo{[1-(2-pyridylmethyl)cyclohexylmethyl]-η^5^-cyclopentadienyl- κN}ruthenium(II)
C18H20INORu
Acta Crystallographica Section E (2006) 62, 6 m1287-m1288
a=6.7349(13)Å b=22.903(5)Å c=11.626(2)Å
α=90.00° β=99.29(3)° γ=90.00°
1,4-Bis(phenylsulfanyl)butane
C16H18S2
Acta Crystallographica Section E (2005) 61, 6 o1890-o1891
a=5.6753(11)Å b=7.7950(16)Å c=16.368(3)Å
α=93.02(3)° β=96.00(3)° γ=90.52(3)°
(R)-(-)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
C11H13N3O
Acta Crystallographica Section E (2006) 62, 7 o2999-o3000
a=9.765(2)Å b=11.552(2)Å c=18.796(4)Å
α=90.00° β=90.00° γ=90.00°
N-(2-Bromothiazol-5-ylmethyl-phthalimide
C12H7Br1N2O2S1
Acta Crystallographica Section E (2006) 62, 6 o2327-o2328
a=7.3539(15)Å b=8.6315(17)Å c=9.794(2)Å
α=108.16(3)° β=93.79(3)° γ=96.41(3)°
(1R,5R,6R)-Ethyl 3-benzyl-2,4-dioxo-3-azabicyclo[3.1.0]hexane-6-carboxylate
C15H15NO4
Acta Crystallographica Section E (2006) 62, 6 o2331-o2332
a=14.185(3)Å b=5.2973(11)Å c=18.661(4)Å
α=90° β=101.26(3)° γ=90°
Catena-Poly[[[(acetonitrile-κN)silver(I)]-μ-[bis(pyrimidin-2- ylsulfanyl)methane-κ^2^N^1^:N^1^] tetrafluoroborate]
C11H11AgN5S2,BF4
Acta Crystallographica Section E (2005) 61, 8 m1658-m1659
a=8.7063(12)Å b=14.7402(16)Å c=24.965(2)Å
α=90.00° β=90.00° γ=90.00°
1,2-bis(phenylsulfanyl)ethane
C14H14S2
Acta Crystallographica Section E (2005) 61, 8 o2482-o2483
a=5.8389(12)Å b=7.6865(15)Å c=14.124(3)Å
α=90.00° β=97.90(3)° γ=90.00°
1,2-Bis(pyrimidin-2-ylsulfanyl)ethane
C10H10N4S2
Acta Crystallographica Section E (2005) 61, 10 o3174-o3175
a=8.0524(16)Å b=19.884(4)Å c=8.1541(16)Å
α=90.00° β=116.57(3)° γ=90.00°
3-Benzotriazol-1-yl 5-tert-butyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
C25H25N5O6
Acta Crystallographica Section E (2006) 62, 1 o72-o73
a=10.332(2)Å b=15.163(3)Å c=16.010(3)Å
α=90.00° β=90.96(3)° γ=90.00°
[μ-1,2-Bis(phenylsulfanyl)ethane-κ^2^S:S]bis[dibromomercury(II)]
C14H14Br4Hg2S2
Acta Crystallographica Section E (2006) 62, 3 m440-m441
a=22.0328(13)Å b=11.6648(7)Å c=8.0759(4)Å
α=90.00° β=103.313(4)° γ=90.00°
Irbesartan bromide sesquihydrate
C25H29N6O,Br,1.5(H2O)
Acta Crystallographica Section E (2007) 63, 12 o4933-o4933
a=12.482(3)Å b=25.285(5)Å c=8.6938(17)Å
α=90.00° β=105.78(3)° γ=90.00°
Hexaaquanickel(II) dinitrate--bis(pyrimidin-2-ylsulfanyl)methane (1/2)
H12NiO62,2(NO3),2(C9H8N4S2)
Acta Crystallographica Section E (2007) 63, 3 m662-m663
a=14.078(3)Å b=8.0546(16)Å c=14.887(3)Å
α=90.00° β=115.56(3)° γ=90.00°
Tetra-μ-acetato-κ^8^O:O-bis{[2-(phenylsulfanylmethyl)pyridine-κN]copper(II)}
C32H34Cu2N2O8S2
Acta Crystallographica Section E (2007) 63, 8 m2172-m2172
a=7.7587(16)Å b=7.9690(16)Å c=13.986(3)Å
α=102.51(3)° β=101.86(2)° γ=94.29(3)°
8-(Pyrimidin-2-ylsulfanylmethyl)quinoline
C14H11N3S
Acta Crystallographica Section E (2006) 62, 9 o3808-o3809
a=9.5743(19)Å b=8.0531(16)Å c=15.951(3)Å
α=90.00° β=96.60(3)° γ=90.00°
Dicumyl peroxide
C18H22O2
Acta Crystallographica Section E (2008) 64, 11 o2128
a=10.040(2)Å b=7.4774(15)Å c=21.016(4)Å
α=90.00° β=90.00° γ=90.00°
2-Methoxy-4-[(4-methylpiperazin-1-yl)iminomethyl]phenol
C13H19N3O2
Acta Crystallographica Section E (2011) 67, 1 o100
a=12.179(2)Å b=18.624(3)Å c=6.0187(10)Å
α=90.00° β=90.00° γ=90.00°
1H-imidazol-3-ium 3-nitrobenzoate
C3H5N2,C7H4NO4
Acta Crystallographica Section E (2009) 65, 5 o1038
a=12.209(2)Å b=12.081(2)Å c=7.3216(15)Å
α=90.00° β=106.38(3)° γ=90.00°